ACC 2018 Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.
EPCCS 2018 An impression of the presentation of dr. Rafel Ramos on diagnosis and clinical management of peripheral artery disease in primary care, given during the Annual EPCCS CV Summit.
Four Heart Rhythm Societies have composed a consensus statement on how to prevent, assess and treat cognitive decline in atrial fibrillation and other arrhythmias.
The European Heart Rhythm Association (EHRA) updated its practical guide on use of non-vitamin K antagonist oral anticoagulants in specific clinical situations and particular patient groups.
Defining statin eligibility based on the predicted CV benefit, rather than the absolute CV risk, shifts statin eligibility to more intermediate CV risk subjects.
In a large, prospective, population-based cohort, the waist-to-hip ratio was more strongly associated with the risk of MI compared with BMI, especially in women.
New data of the ongoing GLORIA-AF registry on use of dabigatran in AF show low rates of major bleeding and stroke, and long-term safety data are consistent with other real-world and RCT evidence.
Maintaining or increasing physical activity was associated with substantial reductions in CVD mortality risk, in a large cohort of patients with angina pectoris or myocardial infarction.
EPCCS Council Already at the second Council meeting, we shift gears from making plans to taking action and bringing the support of the European Primary Cardiovascular Care Community to a higher level.
ACC 2018 Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.
ACC 2018 In the digital mSToPS trial using patient-generated data, a wearable ECG patch improved the rate of AF diagnosis at 1 year compared to routine care.
ACC 2018 In post-MI patients with a low LVEF, WCD reduced total mortality in the immediate post-MI period (<90 days), but not sudden cardiac death.